Pf-06755347 intravenous    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
63特発性血小板減少性紫斑病1

63. 特発性血小板減少性紫斑病 [臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132
Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 311 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03275740
(ClinicalTrials.gov)
July 17, 20176/7/2017A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING TO HEALTHY ADULT MALE PARTICIPANTSPolyradiculoneuropathy, Chronic Inflammatory Demyelinating;Primary Immune ThrombocytopeniaDrug: PF-06755347 intravenous;Drug: Placebo intravenous;Drug: PF-06755347 subcutaneous;Drug: Placebo subcutaneousPfizerNULLRecruiting18 Years55 YearsMale84Phase 1United States;Belgium;New Zealand;United Kingdom